Vir Biotechnology
VIR
VIR
213 hedge funds and large institutions have $827M invested in Vir Biotechnology in 2023 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 96 increasing their positions, 51 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
22% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 51
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
63% less capital invested
Capital invested by funds: $2.23B → $827M (-$1.4B)
Holders
213
Holding in Top 10
2
Calls
$1.94M
Puts
$1.68M
Top Buyers
| 1 | +$17.1M | |
| 2 | +$16.4M | |
| 3 | +$12.6M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9M |
| 5 |
D.E. Shaw & Co
New York
|
+$7.75M |
Top Sellers
| 1 | -$126M | |
| 2 | -$48M | |
| 3 | -$35M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$24.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$17.9M |